Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 21, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - November 21, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/21/17 - A local look at kratom, the opioid-like botanical under fire from the FDA [The Frederick News-Post, Md.]
In Southeast Asia, the plant has been used for years as a substitute for opium, according to the National Center for Complementary and Integrative Health. The FDA, though, thinks differently. "Basically, what the agency is saying is that kratom behaves as an opioid and that it itself has troubling side effects," said Lyndsay Meyer, a spokeswoman f
11/21/17 - AB Science announces the publication of Preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments
Paris, 21 November 2017, 5.45 pm Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine Phase 3 clinical studies on-going for masitinib-gemcitabine combination in pancreatic cancer, refractory peripheral T-cell lymphoma and refractory ovarian...
11/21/17 - AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
Lausanne, Switzerland, November 21, 2017- AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will host a Key Opinion Leader luncheon meeting on the importance of Tau as a target in Alzheimer's disease and other neurodegenerative diseases on Decem
11/21/17 - ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 10:00 a.m. Eastern Time
11/21/17 - Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor
Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that Dr. Gabriel Mbalaviele presented data from pre-clinical studies of Aclaris...
11/21/17 - Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole
VANCOUVER- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent Office has issued an intention to grant a European patent for AQS1301, Aequus' once-weekly transdermal patch containing aripiprazole. This is the eighth...
11/21/17 - Agency to crack down on stem cell offerings
WASHINGTON U.S. health authorities announced plans Thursday to crack down on doctors pushing stem cell procedures that pose the gravest risks to patients amid an effort to police a burgeoning medical field that previously has received little oversight. FDA officials said they will focus their enforcement efforts on bad actors who inject st
11/21/17 - Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib in Patients with IDH1 Mutant Positive Glioma
SAN FRANCISCO- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were present
11/21/17 - AGLOAN-Tech, Retailers Send Stocks Up Monday
U.S. stocks rose Monday as a mix of smaller, U.S.- focused companies, technology firms and banks climbed. Merck fell after a good report from competitor Roche about a drug that competes with Merck' s cancer medication Keytruda. That's probably going to be the case throughout the week as the Thanksgiving holiday approaches and investors turn their a
11/21/17 - AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30 a.m.
AIT Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that management will hold a clinical update meeting on November 28, 2017 at 7:30 a.m. to discuss data from its NO-NTM Phase 2 clinical t
11/21/17 - Altimmune to Present at the 29th Annual Piper Jaffray Conference
Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that Bill Enright, president and chief executive officer of Altimmune, will present a corporate overview at the 29 th Annual Piper Jaffray Conference, taking place November 28-29, 2017 in New York, NY.. About Altimmune Altimmune is a clinical-stage immunotherapeutics co
11/21/17 - Ampio Announces Start of Open Label Extension Study to Support Commercial Label of Repeat Administration of Ampion in Severe Osteoarthritis of the Knee
ENGLEWOOD, Colo.- Ampio Pharmaceuticals, Inc. announced the beginning of an Open Label Extension study of Ampion in patients with severe osteoarthritis of the knee. The OLE study offers patients an opportunity to receive repeat injections of Ampion after they have completed the pivotal clinical trial. This OLE study will address the regulatory requ
11/21/17 - APNewsBreak: Startup could bring back Vioxx for hemophilia
Could there be a second life for the once-popular arthritis pill Vioxx? Drugmaker Merck voluntarily pulled it off the market in 2004 because it raised the risk of heart attacks and strokes. Now a startup pharmaceutical company is working to bring Vioxx back to treat joint pain in patients with the bleeding disorder hemophilia. The Massachusetts com
11/21/17 - ARCA biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases
WESTMINSTER, Colo.- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office's issuance of a patent on methods of treating cardiovascular disease and conditions with a thiol-substituted isosorbide...
11/21/17 - Auto-Injectors Market Expected to Witness a Sustainable Growth over 2016 - 2026: The market is anticipated to exhibit a CAGR of 15.1% during the forecast period and is projected to be valued at nearly US$ 7,000 Mn by the end of 2026.
Valley Cottage, NY 11/20/2017 Improving healthcare infrastructure across several countries and regions, coupled with availability of well-developed manufacturing units, facilitates the growth of medical device businesses. In the report, titled "Auto-Injectors Market: Global Industry Analysis and Opportunity Assessment, 2016-2026," nearly...
11/21/17 - BioLineRx Reports Third Quarter 2017 Financial Results
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017. Initiation of two additional Phase 1 b/2 studies under collaboration with Genentech, following the first study which was initiated in July 2017. All studies are explorin
11/21/17 - BioPharmX Corporation Announces Pricing of Public Offering
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, today announced the pricing of an underwritten public offering of 73,500,000 shares of its common stock, together with accompanying Series A common warrants to purchase an aggregate of 73,500,000 shares of common stock and Series B common...
11/21/17 - Biosimilars Market: 5 Companies You Know and Five Companies You Need to Know
ROCKVILLE, Md., Nov. 21, 2017/ PRNewswire/ Some of the world's largest biopharmaceutical products, among the highest revenue generators in the pharmaceutical industry, may face competition from so-called "biosimilars," according to a new report from healthcare market research firm Kalorama Information. These close copies of biodrugs are coming to
11/21/17 - BOC Sciences Newly Launched Inhibitor Exatecan Mesylate for Anticancer Drug Research
On November 21, 2017, the world leading chemical supplier BOC Sciences launched exatecan mesylate, adding to its best-selling inhibitor categories. Due to its great anticancer potential, exatecan mesylate has been broadly tested in anticancer clinical trials. This move of BOC Sciences is expected to bring much convenience for researchers who are se
11/21/17 - Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma
PETACH TIKVA, Israel- Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that its previously majority owned subsidiary OphthaliX, Inc. has successfully completed a merger with Wize Pharma Ltd.. As a result of the merger, Can-
11/21/17 - Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
Cancer Prevention Pharmaceuticals, a clinical stage biotechnology company, today announced it will give a corporate presentation at the Piper Jaffray 29 th Annual Healthcare Conference on November 28, 7:50 -8: 10 a.m. ET at the Lotte New York Palace in New York City. In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. th
11/21/17 - Catabasis Pharmaceuticalsto Present at 29th Annual Piper Jaffray Healthcare Conference
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present an overview of the company in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 2:00pm ET at the Lotte New York Palace in New York, NY.
11/21/17 - Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse in Ambulatory Patients with Spinal Muscular Atrophy (SMA)
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the initiation of a company-sponsored, adequate and well-controlled, proof-of-concept clinical trial evaluating safety,...
11/21/17 - Celsion Announces Publication of the Study of ThermoDox + Ultrasound, TARDOX Study Protocol in the Journal of Therapeutic Ultrasound [Syrian Arab News Agency]
-Celsion Corporation today announced publication of the manuscript, "Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin using focused ultrasound in patients with liver tumours," in the Journal of Therapeutic Ultrasound 2017 5:28. The TARDOX Study, whic
11/21/17 - Cerecor Acquires TRx Pharmaceuticals
BALTIMORE, MD- Cerecor Inc. and TRx Pharmaceuticals, LLC today announced that the companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals, LLC and its franchise of commercial medications led by Poly-Vi-Flor and Tri-Vi-Flor and a merger agreement in which Cerecor will acquire Zy
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement